

October 31, 2010

Dear Colleague:

This letter announces an important update to our test **QuantiFERON®-TB Gold (Incubated) [6110]**. This change affects reference ranges and adds quantitative values. Values for the individually analyzed tubes (Nil, Mitogen-Nil, and TB Ag-Nil) are being provided following recent recommendations from the CDC (MMWR; June 25, 2010 / Vol. 59 / No. RR-5). The Nil value adjusts for patient sample background, heterophile antibody effects, or non-specific interferon. The Mitogen-Nil serves as a patient positive control. The result "Negative" or "Positive" or "Indeterminate" is calculated from these values using an FDA approved algorithm run on QuantiFERON® software.

Effective January 3, 2011 Specialty Laboratories will discontinue providing Hemocult® SENSEA® (BeckmanCoulter, Inc.) test cards. We will continue to accept Hemocult SENSEA cards for testing through January 31, 2011. We will continue to offer the InSure® test, **FECAL GLOBIN BY IMMUNOCHEMISTRY [S51000]**™, a Fecal Immunochemical Test (FIT) that detects human hemoglobin in fecal specimens. Reliable medical studies demonstrate that FIT has medical benefits compared to traditional guaiac-based testing, which motivated our decision to discontinue support for Hemocult SENSEA tests. A letter with further clinical details about this change is available on our website www.specialtylabs.com.

Please also note that CMS has recently implemented a policy change that went into effect July 6, 2010. All Ordering/Referring providers must be in the Medicare Provider Enrollment Chain and Ownership System (PECOS) for laboratory services billable under Medicare Part B. Specialty Laboratories is required to ensure that all Ordering and Referring providers have enrollment records in PECOS that contain the NPIs and are of a type/specialty that is eligible to order or refer to the Medicare Part B program. It is important to note that Specialty Laboratories will be billing the ordering facility for any tests ordered or referred by a provider who is not enrolled in PECOS on and after January 1, 2011. This new ruling applies even if the provider does not directly submit Medicare claims for payment. Providers may submit the enrollment application over the internet at <https://pecos.cms.hhs.gov/pecos/login.do> or by completing and mailing to the Medicare contractor the Medicare enrollment application.

We thank you for choosing *Specialty* and look forward to your continued support. For additional information, please visit our Web site at www.specialtylabs.com or contact Client Relations at 800-421-4449.

Respectfully Yours,



Basel Kashlan, M.D., FCAP
Laboratory Director

New Tests (*Specialty*):

4181U Opiates Confirmation, Enhanced Sensitivity, Urine (Available November 15)

Component	Method	Cut-off/Units
Codeine	LC-MS-MS	50 ng/mL
Hydrocodone	LC-MS-MS	50 ng/mL
Hydromorphone	LC-MS-MS	50 ng/mL
Morphine	LC-MS-MS	50 ng/mL
Oxycodone	LC-MS-MS	50 ng/mL
Oxymorphone	LC-MS-MS	50 ng/mL

Specimen/Stability Urine 10 (5) mL: Ambient 14 days, Refrigerated 14 days, Frozen 30 days
 Collection Instructions Do not use any preservatives or additives.
 Schedule Tuesday, Thursday, Saturday
 Report Next day
 CPT Code 83925
 Regulatory Status Laboratory Developed Test
 Always Statement Limit of quantitation:
 Codeine 50 ng/mL
 Hydrocodone 50 ng/mL
 Hydromorphone 50 ng/mL
 Morphine 50 ng/mL
 Oxycodone 50 ng/mL
 Oxymorphone 50 ng/mL

Clinical Utility Confirmation of screen positive results.

4496U Morphine, Quantitative, Urine (Available November 15)

Component	Method	Cut-off/Units
Morphine	LC-MS-MS	100 ng/mL

Specimen/Stability Urine 20 (10) mL: Ambient 7 days, Refrigerated 14 days, Frozen 30 days
 Collection Instructions Collect random urine.
 Schedule Tuesday, Thursday, Saturday
 Report Next day
 CPT Code 83925
 Regulatory Status Laboratory Developed Test

New Tests (*Specialty*): (cont'd)

4060UR Heavy Metals Comprehensive Panel, Random Urine (Available November 15)

Component	Method	Reference Range/Units
Arsenic Random Urine	ICP/MS	<51 mcg/g creat
Lead Random Urine	ICP/MS	<10 mcg/g creat
Mercury Random Urine	ICP/MS	<5 mcg/g creat
Cadmium Random Urine	ICP/MS	<3.1 mcg/g creat
Cobalt Random Urine	ICP/MS	<2.9 mcg/L
Thallium Random Urine	ICP/MS	<0.5 mcg/g creat
Creatinine Random Urine	S	0 – 6 Months: 2.0 – 32.0 mg/dL
		7 – 11 Months: 2.0 – 36.0
		1 – 2 Years: 2.0 – 128.0
		3 – 8 Years: 2.0 – 149.0
		9 – 12 Years: 2.0 – 183.0
		>12 Years (Male): 20.0 – 370.0 >12 Years (Female): 20.0 – 320.0

Specimen/Stability Urine 7.0 (3.5) mL: Ambient 48 hours, Refrigerated 5 days, Frozen 14 days

Collection Instructions Collect random urine in an acid-washed polypropylene or polyethylene collection container. Use powderless gloves to pour sample into acid washed shipping container. Cap securely and ship refrigerated. For industrial monitoring, collect specimen pre-shift.

Patient Preparation: Patients should refrain from taking vitamins, mineral or herbal supplements at least one week prior to specimen collection.

Dietary Restrictions: Patient should refrain from eating seafood at least three days prior to specimen collection. Patient should refrain from taking mineral supplements at least three days prior to sample collection.

Schedule Tuesday, Thursday, Saturday

Report Within 2 days

CPT Code 82175, 83655, 83825, 82300, 83018x2, 82570

Regulatory Status Metals: Laboratory Developed Test; Creatinine: FDA Approved

Always Statement Arsenic:

For Nonexposed Adult	Less than or equal to 50 mcg/g creat
Biological Exposure Index (end of shift/work week)	Less than or equal to 50 mcg/g creat

Mercury:

For Nonexposed Adult	Less than or equal to 4 mcg/g creat
Biological Exposure Index (preshift)	Less than or equal to 35 mcg/g creat

Cadmium:

For Nonexposed Adult	Less than or equal to 1.2 mcg/g creat
OSHA Reference Range For Industrial Exposure	Less than or equal to 3.0 mcg/g creat

Test Changes:

2351 Antideoxyribonuclease-B Antibodies
Effective Immediately
Name DNase-B Antibody (**NEW**)

2361 Ova & Parasite: Routine Exam
Effective Immediately
Specimen/Stability Stool SAF Fixative 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Stool Formalin 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Stool PVA 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Stool EcoFix 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Sputum (Induced) 2.0 (1.0) mL: Ambient 14 days, Refrigerated 14 days
Sterile Container/Tube 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Urine 2.0 (1.0) mL: Ambient 14 days
Note: Stool EcoFix specimens now accepted.

2363 Ova & Parasite: *Coccidia* Evaluation
Effective Immediately
Specimen/Stability Stool SAF Fixative 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Stool Formalin 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Stool PVA 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Stool EcoFix 2.0 (1.0): Ambient 14 days, Refrigerated 14 days
Sputum (Induced) 2.0 (1.0) mL: Ambient 14 days, Refrigerated 14 days
Note: Stool PVA and EcoFix specimens now accepted.

3750 Respiratory Allergen Profile Region XI
Effective Immediately
Component Dog Epithelium IgE (**REMOVE**)
Component Dog Dander IgE (**ADD**)
Note: Dog Epithelium is being discontinued by the vendor.
Also Affected DOS Codes 3751, 3752, 3753

4856UR Magnesium Random Urine [ICP-OES]
Effective Immediately
Component Magnesium Random Urine (**NEW NAME**)
Note: The component Magnesium/Creatinine Ratio will now be called Magnesium Random Urine.

4877 Zinc
Effective Immediately
Collection Instructions Separate plasma or serum from cells within two hours. Pour off (do not pipette) separated plasma or serum to a plastic transfer vial from a Specialty "Trace element and metal free" collection kit. Alternatively, pour off (do not pipette) separated plasma or serum to a second non-additive Royal blue-top tube for transport. Hemolyzed samples, plasma or serum not separated from cells within two hours or samples submitted in non-trace metal certified containers are not acceptable.

Test Changes: (cont'd)

4884W Cobalt Whole Blood

Effective Immediately
Specimen/Stability Whole Blood EDTA Trace Metal 4.0 (2.0): Ambient 48 hours,
Refrigerated 5 days
Whole Blood NaHep Trace Metal 4.0 (2.0): Ambient 48 hours,
Refrigerated 5 days
Note: Increased ambient stability

4886UR Thallium Random Urine

Effective Immediately
Component Thallium Random Urine **(NEW NAME)**
Note: The component Thallium/Creatinine Ratio will now be called Thallium Random Urine.

9620 Nuclear Matrix Proteins (NMP)

Effective Immediately
CPT Code 83520 **(NEW)**

1092 Thyroid Stimulating Immunoglobulins

Effective November 23
Reference Range <140% of baseline of Reference Control **(NEW)**
Always Statement Thyroid stimulating immunoglobulins (TSI) can engage the TSH receptors resulting in hyperthyroidism in Graves' disease patients. TSI levels can be useful in monitoring the clinical outcome of Graves' disease as well as assessing the potential for hyperthyroidism from maternal-fetal transfer.

NOTE: A serum TSH level greater than 350 micro-International Units/mL can interfere with the TSI bioassay and potentially give false positive results.

Also Affected DOS Codes 1091, 3060

1820 Human Papillomavirus DetectR™

Effective November 23
Always Statement Tested by Qiagen (Digene) Hybrid Capture II for HPV High Risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 and HPV Low Risk types 6, 11, 42, 43 and 44.
The performance characteristics of this assay(s) have been determined by Specialty Laboratories. Performance characteristics refer to the analytical performance of the test when used to test SurePath or vaginal specimens.
Also Affected DOS Code 1824

Test Changes: (cont'd)

1821	Human Papillomavirus High Risk DetectR™	
Effective	November 23	
Always Statement	Tested by Qiagen (Digene) Hybrid Capture II for HPV High Risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 which are typically associated with all grades of squamous intraepithelial lesions, especially high-grade squamous intraepithelial lesions and invasive cancer of the cervix. The performance characteristics of this assay(s) have been determined by Specialty Laboratories. Performance characteristics refer to the analytical performance of the test when used to test SurePath or vaginal specimens.	
1821R	Human Papillomavirus High Risk DetectR™ Anal/Rectal	
Effective	November 23	
Always Statement	Tested by Qiagen (Digene) Hybrid Capture II for HPV High Risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 which are typically associated with all grades of squamous intraepithelial lesions, especially high-grade squamous intraepithelial lesions and invasive cancer of the cervix. The performance characteristics of this assay(s) have been determined by Specialty Laboratories. Performance characteristics refer to the analytical performance of the test when used to test anal/rectal specimens in Qiagen (Digene) Transport Medium or ThinPrep vials.	
1822	Human Papillomavirus High & Low Risk DetectR™	
Effective	November 23	
Component	HPV High & Low Risk DetectR™ (REMOVE)	
Component	HPV DNA High Risk (ADD)	
Reference Range	Not detected	
Always Statement	Tested by Qiagen (Digene) Hybrid Capture II for HPV High Risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 which are typically associated with all grades of squamous intraepithelial lesions, especially high-grade squamous intraepithelial lesions and invasive cancer of the cervix.	
Component	HPV DNA Low Risk (ADD)	
Reference Range	Not detected	
Always Statement	Tested by Qiagen (Digene) Hybrid Capture II for HPV Low Risk types 6, 11, 42, 43 and 44. The performance characteristics of this assay(s) have been determined by Specialty Laboratories. Performance characteristics refer to the analytical performance of the test when used to test SurePath or vaginal specimens.	
Also Affected	Reflex of DOS Code 1824	

Test Changes: (cont'd)

1822R	Human Papillomavirus High & Low Risk DetectR™ Anal/Rectal
Effective	November 23
Component	HPV High & Low Risk DetectR™ (REMOVE)
Component	HPV DNA High Risk (ADD)
Reference Range	Not detected
Always Statement	Tested by Qiagen (Digene) Hybrid Capture II for HPV High Risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 which are typically associated with all grades of squamous intraepithelial lesions, especially high-grade squamous intraepithelial lesions and invasive cancer of the cervix.
Component	HPV DNA Low Risk (ADD)
Reference Range	Not detected
Always Statement	Tested by Qiagen (Digene) Hybrid Capture II for HPV Low Risk types 6, 11, 42, 43 and 44. The performance characteristics of this assay(s) have been determined by Specialty Laboratories. Performance characteristics refer to the analytical performance of the test when used to test anal/rectal specimens in Qiagen (Digene) Transport Medium or ThinPrep vials.
2362	Ova & Parasite: Comprehensive Exam w/<i>Coccidia</i> Evaluation
Effective	November 23
Specimen/Stability	Stool SAF Fixative 2.0 (1.0): Ambient 14 days, Refrigerated 14 days Stool Formalin 2.0 (1.0): Ambient 14 days, Refrigerated 14 days Stool PVA 2.0 (1.0): Ambient 14 days, Refrigerated 14 days Stool EcoFix 2.0 (1.0): Ambient 14 days, Refrigerated 14 days Sputum (Induced) 2.0 (1.0) mL: Ambient 14 days, Refrigerated 14 days Note: Stool EcoFix specimens now accepted; Urine and Sterile Container/Tube are no longer accepted.
3496	Methylmalonic Acid
Effective	November 23
Specimen/Stability	Serum 3.0 (2.0) mL: Ambient 30 days, Refrigerated 30 days, Frozen 30 days Note: Ambient specimens now accepted; increased refrigerated and decreased frozen stability.
3507	Vitamin B12 EvaluatR™
Effective	November 23
Specimen/Stability	Serum 5.0 (4.0) mL: Ambient 48 hours, Refrigerated 7 days, Frozen 30 days Note: Ambient specimens now accepted; increased refrigerated and decreased frozen stability.
3605	Pernicious Anemia EvaluatR™ w/Reflex
Effective	November 23
Specimen/Stability #1	Serum 5.0 (4.0) mL: Ambient 48 hours, Refrigerated 7 days, Frozen 30 days Note: Ambient and refrigerated specimens now accepted; decreased frozen stability.
Specimen/Stability #2	Serum 2.0 (1.0) mL: Frozen 3 months

Test Changes: (cont'd)

4861UR Lead Urine Random

Effective November 23
Component Lead Urine mcg/L **(REMOVE)**
Component Creatinine mg/dL (no change)
Component Lead Random Urine mcg/g creat **(NEW NAME)**
Note: Lead results will no longer be reported in units of mcg/L. The component Lead/Creatinine Ratio will now be called Lead Random Urine.
Also Affected DOS Code 4080UR

4867UR Arsenic Urine Random

Effective November 23
Component Arsenic Urine mcg/L **(REMOVE)**
Component Creatinine mg/dL (no change)
Component Arsenic Random Urine mcg/g creat **(NEW NAME)**
Note: Arsenic results will no longer be reported in units of mcg/L. The component Arsenic/Creatinine Ratio will now be called Arsenic Random Urine.
Also Affected DOS Code 4080UR

4868UR Cadmium Urine Random

Effective November 23
Component Cadmium Urine mcg/L **(REMOVE)**
Component Creatinine mg/dL (no change)
Component Cadmium Random Urine mcg/g creat **(NEW NAME)**
Note: Cadmium results will no longer be reported in units of mcg/L. The component Cadmium/Creatinine Ratio will now be called Cadmium Random Urine.

4872 Manganese Serum/Plasma

Effective November 23
Reference Range < 1.2 mcg/L **(NEW)**

4873UR Mercury Urine Random

Effective November 23
Component Mercury Urine mcg/L **(REMOVE)**
Component Creatinine mg/dL (no change)
Component Mercury Random Urine mcg/g creat **(NEW NAME)**
Note: Mercury results will no longer be reported in units of mcg/L. The component Mercury/Creatinine Ratio will now be called Mercury Random Urine.
Also Affected DOS Code 4080UR

8766 Varicella-Zoster Virus Antibody (IgM)

Effective November 23
Specimen/Stability Serum 1.0 (0.5) mL: Ambient 7 days, Refrigerated 14 days, Frozen 2 months
Note: Plasma EDTA is no longer accepted.

Test Changes: (cont'd)

3182 Growth Hormone

Effective	December 7
Specimen/Stability	Serum 2.0 (1.0) mL: Ambient 7 days, Refrigerated 7 days, Frozen 28 days Note: Increased ambient and decreased frozen stability.
Reference Range	< 20 Years: <13.1 ng/mL (NEW) >= 20 Years: <10.1 ng/mL (NEW)
Always Statement	Because of a pulsatile secretion pattern, random (unstimulated) growth hormone (GH) levels are frequently undetectable in normal children and adults and are not reliable for diagnosing GH deficiency. Regarding suppression tests, failure to suppress GH is diagnostic of acromegaly. Typical GH response in healthy subjects: Using the glucose tolerance (GH suppression) test, acromegaly is ruled out if the patient's GH level is <1.0 ng/mL at any point in the timed sequence. Using GH stimulation testing, the following result at any point in the timed sequence rules out GH deficiency: Adults (>or =20 years) Insulin Hypoglycemia: > or = 5.1 ng/mL Arginine/GHRH: > or = 4.1 ng/mL Children (<20 years) All Stimulation Tests: > or = 10 ng/mL
Also Affected	DOS Codes 3171, 3175, 3185, 3195

6110 QuantiFERON®-TB Gold (Incubated)

Effective	December 7
Reference Range	Negative (NEW)
Component	Nil (NEW) , reported in IU/mL
Component	Mitogen-Nil (NEW) , reported in IU/mL
Component	TB Ag-Nil (NEW) , reported in IU/mL
Always Statement	The Nil value adjusts for patient sample background, heterophile antibody effects, or non-specific interferon. The Mitogen-Nil serves as a patient positive control. The result "Negative" or "Positive" or "Indeterminate" is calculated from these values using an FDA approved algorithm run on Quantiferon® software. The performance of the Quantiferon® TB Gold IT (QFT-GIT) test has not been extensively evaluated in children younger than 17 years of age. Therefore, there is limited published data to document the performance of QFT-GIT in this age group. According to the CDC (MMWR, JUNE 25, 2010, Vol. 59, RR-5), QFT-GIT should not be used for children <5 years of age.

Test Changes: (cont'd)

8137	Hepatitis B Virus DNA UltraQuant®
Effective	December 7
Name	Hepatitis B DNA Quantitative Real-Time PCR
Specimen/Stability	Serum 3.0 (2.5) mL: Ambient 3 days, Refrigerated 7 days, Frozen 6 weeks
Alt Specimen	Plasma EDTA 3.0 (2.5) mL: Ambient 3 days, Refrigerated 7 days, Frozen 6 weeks Plasma PPT 3.0 (2.5) mL: Ambient 3 days, Refrigerated 7 days, Frozen 6 weeks Note: Plasma ACD no longer accepted; decreased ambient, refrigerated and frozen serum and EDTA plasma stability; increased ambient and refrigerated, decreased frozen plasma PPT stability.
Collection Instructions	See "Guidelines for Shipping Infectious Substances". Serum: Collect whole blood in red-top plastic SST tube with separator gel. Plasma: Collect whole blood in either EDTA lavender tube or PPT Vacutainer plasma preparation tube. Mix gently. Separate plasma or serum from cells within 1 day of collection by centrifugation at 800 to 1600 X g for 20minutes at room temperature. Transfer the plasma or serum to a properly identified, sterile screw cap vial and ship frozen.
Methodology	RT-PCR (NEW)
FDA Status	FDA Approved (Analyte Specific Reagent statement to be removed)
Reference Range	Hepatitis B DNA <29 IU/mL (NEW) Hepatitis B DNA <169 copies/mL (NEW)
Always Statement	Approximately 5.82 copies = 1 IU Approximately 150,000 copies = 1 pg The method used in this test is Real-Time PCR of the pre-core region of the circular HBV genome. This test was performed using the COBAS®AmpliPrep/COBAS®TaqMan® 48 Analyzer HBV Test Kit (Roche Molecular Systems, Inc).
Also Affected	DOS Code 2479

Test Changes: (cont'd)

8141	Hepatitis B Virus DNA DetectR™
Effective	December 7
Name	Hepatitis B DNA Qualitative Real-Time PCR
Specimen/Stability	Serum 3.0 (2.5) mL: Ambient 3 days, Refrigerated 7 days, Frozen 6 weeks
Alt Specimen	Plasma EDTA 3.0 (2.5) mL: Ambient 3 days, Refrigerated 7 days, Frozen 6 Weeks Plasma PPT 3.0 (2.5) mL: Ambient 3 days, Refrigerated 7 days, Frozen 6 weeks
Collection Instructions	Note: Plasma PPT now accepted; plasma ACD no longer accepted; decreased ambient, refrigerated and frozen stability. See "Guidelines for Shipping Infectious Substances". Serum: Collect whole blood in red-top plastic SST tube with separator gel. Plasma: Collect whole blood in either EDTA lavender tube or PPT Vacutainer plasma preparation tube. Mix gently. Separate plasma or serum from cells within 1 day of collection by centrifugation at 800 to 1600 X g for 20minutes at room temperature. Transfer the plasma or serum to a properly identified, sterile screw cap vial and ship frozen.
Methodology	RT-PCR (NEW)
FDA Status	FDA Approved (Analyte Specific Reagent statement to be removed)
Always Statement	The method used in this test is Real-Time PCR of the pre-core region of the circular HBV genome. This test was performed using the COBAS®AmpliPrep/COBAS®TaqMan® 48 Analyzer HBV Test Kit (Roche Molecular Systems, Inc).

4870UR	Copper Random Urine
Effective	December 21
Component	Copper Urine mcg/L (REMOVE)
Component	Creatinine mg/dL (no change)
Component	Copper Random Urine mcg/g creat (NEW NAME)
Always Statement	Note: Copper results will no longer be reported in units of mcg/L. The component Copper/Creatinine Ratio will now be called Copper Random Urine. 2 nd Voided AM Urine for Nonexposed Adult Females: 6.7-18.6 mcg/g creat 2 nd Voided AM Urine for Nonexposed Adult Males: 6.4-14.3 mcg/g creat

The CPT Codes provided are based on AMA Guidelines and are for informational purposes only. CPT Coding is the sole responsibility of the billing party. Please direct any questions regarding CPT Coding to the payer being billed.

New Referral Tests:

The following tests are now available from Quest Diagnostics and may be referred through Specialty Laboratories.

- S52292 Testoserone, Free, Bioavailable, & Total, LC/MS/MS [14966X]**
Test performed by Quest Diagnostics, San Juan Capistrano
- S52294 Thrombin Clotting Time w/Reflex to Mixing Study [144598]**
Test performed by Quest Diagnostics, Chantilly
- S52301 FISH, Neonatal Screen [36053]**
Test performed by Quest Diagnostics, San Juan Capistrano
- S52302 Drug Screen, Comprehensive (Urine) [6635X]**
Test performed by Quest Diagnostics, Chantilly

Please call client relations at 800-421-4449 or visit our website at www.specialtylabs.com for ordering information.

Discontinued Tests:

Effective Immediately:

E2	Allergen – Dog Epithelium IgE Recommended replacement: E5 – Allergen – Dog Dander IgE Test performed at Specialty Laboratories
E2G	Allergen – Dog Epithelium IgG Recommended replacement: E5G – Allergen – Dog Dander IgG Test performed at Specialty Laboratories
RK203	Allergen – Phospholipase IgE No replacement
S51187	Everolimus [0092118] Recommended replacement is S18883 - Everolimus, Blood Test [2066B] Test performed by National Medical Services
S51821	Outer Membrane Protein (OMP) IgA [0051384] No replacement
S42951	CYTOCHEMISTRY STAIN FOR SUDAN BLACK No replacement
S42952	CYTOCHEMISTRY STAIN FOR LIPASE No replacement
S48577	JC VIRUS DETECTION BY FISH [81107] No replacement
S48623	PS2 ER-RELATED PROTEIN No replacement
S48683	IHC CA 15-3 No replacement
S49517	RETICULIN IHC No replacement
S50553	IHC-HEPATITIS B SURFACE ANTIGEN [3711] No replacement
S50555	IHC-HEPATITIS B CORE ANTIGEN No replacement
S50558	IHC-HEPATITIS C ANTIGEN [TORDJI-22] No replacement
S51175	IHC STAIN-ADENOVIRUS No replacement

Discontinued Tests: (cont'd)

Effective Immediately:

S51188 IHC-HALES COLLOID STAIN [STAIN ONLY-8003005]
No replacement

Effective October 31:

S40335 Thymidine Kinase
No replacement

S41160 CA 72-4
No replacement

Effective December 1:

S43580 Cathartic Laxative Urine Panel [1033]
Recommended replacement is S52306 - Laxatives Panel (Qual.), Urine (2499U)
Test performed by National Medical Services

S50972 Fungitell®
Recommended replacement is S52305 - Fungitell® (1-3)-β-D-Glucan Assay (55310)